Effect of tissue factor knockdown on the growth, invasion, chemoresistance and apoptosis of human gastric cancer cells

Yu, Yiping; Hou, Xudong; Li, Yumin

doi:10.3892/etm.2014.1591

Cited by 8 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been confirmed that the expression of TF is a biomarker for preoperative diagnosis and the prognosis of malignant tumors ( 6 , 7 ). However, TF also affects the clinical progression of malignant tumors by affecting the proliferation, infiltration and metastasis of cancer cells ( 8 – 10 ); for this reason, TF is a potential target for the treatment of malignant tumors ( 11 ). However, few previous studies have reported the expression of TF in cervical cancer.…”

Section: Introductionmentioning

confidence: 99%

Expression of tissue factor in human cervical carcinoma tissue

et al. 2018

View full text Add to dashboard Cite

The present study aimed to investigate tissue factor (TF) expression in cervical cancer and explore its association with disease progression. A total of 258 cervical cancer tissues and their adjacent normal tissues were collected between September 2014 and September 2016. TF expression was detected in the tissue samples by immunohistochemistry and western blot analysis. Associations between the expression of TF and clinical stage, differentiation status and metastasis of cancer cells were examined. The mean immunohistochemistry score of TF expression in cervical cancer tissues was 2.86±1.76, which was significantly increased compared with the adjacent normal tissues (0.28±0.45). The expression of TF was also significantly associated with the clinical stage, lymph node metastasis and distant metastasis of cancer cells. Immunohistochemistry staining and western blot analysis demonstrated that TF expression in cervical cancer tissues significantly increased as the clinical stage increased. TF expression in tumor tissues from patients with lymph node metastasis was significantly increased compared with samples from patients without lymph node metastasis. TF expression was also significantly increased in patients with distant metastasis compared with those without. In conclusion, TF is highly expressed in cervical cancer tissues and high expression of TF may enhance the invasion and metastasis of cervical cancer cells.

show abstract

Section: Introductionmentioning

confidence: 99%

Expression of tissue factor in human cervical carcinoma tissue

et al. 2018

View full text Add to dashboard Cite

show abstract

“…TF is produced by tumor cells and stimulates production of interleukin-1 and vascular endothelial growth factor (VEGF) within the body, both of which promote a hypercoagulable state when they interact with platelets and endothelial cells. 23,24 Thus, TF has been associated with tumor-associated thrombosis, favoring tumor proliferation and metastasis. Furthermore, TF may enhance tumor spread and metastasis through intracellular signal transduction.…”

Section: Pharmacologymentioning

confidence: 99%

“…TF has been demonstrated to activate protease activated receptor 2, which in turn activates a few key signaling pathways, including p44/42 mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3. 23,24 By hydrolyzing prothrombin, TF may increase production and release of cytokines, including interleukin-1β and interleukin 8, that regulate inflammation and promote invasion of tumor cells. 23,24 It is also theorized that TF may upregulate expression of plasminogen activator receptors.…”

Section: Pharmacologymentioning

confidence: 99%

A review of the novel tissue factor antibody–drug conjugate: Tisotumab vedotin

Luu

Chu

Chang

2022

J Oncol Pharm Pract

View full text Add to dashboard Cite

Objective To review and compare the pharmacology, efficacy, and safety of the novel tissue factor antibody–drug conjugate, tisotumab vedotin Data sources Literature search was performed through PubMed MEDLINE, Google Scholar, ClinicalTrials.gov, and the Food and Drug Administration. Data summary Tisotumab vedotin, a novel tissue factor antibody–drug conjugate, was granted accelerated approval by the US FDA on 20 September 2021 for adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tisotumab vedotin demonstrated clinical efficacy in a number of solid tumors in innovaTV 201 and more specifically in cervical cancer in the pivotal phase 2 innovaTV 204. In the single-arm innovaTV 204 study, 101 patients with recurrent or metastatic cervical cancer received intravenous tisotumab vedotin at the recommended dose of 2 mg/kg every 3 weeks until disease progression or unacceptable toxicity. The independent review committee confirmed an objective response rate of 24% with 7% complete responses and 17% partial responses. Tisotumab vedotin is associated with several notable adverse events with data from innovaTV 204 including ocular toxicity, hemorrhage, and peripheral neuropathy. Ninety-two percent of patients experienced treatment-related adverse events with 28% experiencing an adverse event of grade 3 or higher. Conclusions Metastatic cervical cancer has a high risk of relapse with few effective second-line therapeutic options. Current guidelines recommend single agent tisotumab vedotin as a possible option. Ongoing trials will further define its place in therapy.

show abstract

“…5E). The altered expression of all these genes have been associated with an increased susceptibility to apoptosis (44)(45)(46)(47)(48)(49)(50)(51)(52), suggesting that the synergistic cell death observed with OTX+PAZO could be mediated by apoptosis.…”

Section: Transcriptome Analysis Uncovered a Higher Expression Of Apop...mentioning

confidence: 99%

Ex vivo drug testing in an ultra-rare sarcoma reveals therapeutic vulnerability and resistance

Chan

Luo

Chen

et al. 2022

Preprint

View full text Add to dashboard Cite

Solitary fibrous tumors (SFTs) are rare soft tissue sarcomas for which therapeutic options are limited and ineffective. We successfully demonstrated how functional personalized treatment was implemented in the clinic for an ultra-rare sarcoma with otherwise limited options, through a combined strategy of patient-derived model development and computational drug analytics. Molecular profiling of tumours and patient-derived models uncovered potential biomarkers to predict responses to specific drugs. We generated patient-derived SFT cells (PDSC) and used a computational combinatorial drug screening analytics platform, Quadratic Phenotypic Optimization Platform (QPOP), to determine therapeutic vulnerability and resistance in an ultra-rare locally recurrent brain SFT and its distant liver metastasis. QPOP derived and ranked the efficacy of 531,441 drug combinations, revealing BETi-pazopanib synergy in the liver lesion that outperforms standard-of-care combination doxorubicin-ifosfamide, which was antagonistic. In tumour and PDSC from the pazopanib-resistant brain lesion, transcriptomic analyses identified the UGT1A family as potential biomarkers of pazopanib resistance. Eribulin sensitivity was predicted to be shared across both lesions. Our patient was therefore treated with eribulin and successfully gained clinically meaningful disease control.

show abstract

Effect of tissue factor knockdown on the growth, invasion, chemoresistance and apoptosis of human gastric cancer cells

Cited by 8 publications

References 24 publications

Expression of tissue factor in human cervical carcinoma tissue

Expression of tissue factor in human cervical carcinoma tissue

A review of the novel tissue factor antibody–drug conjugate: Tisotumab vedotin

Ex vivo drug testing in an ultra-rare sarcoma reveals therapeutic vulnerability and resistance

Contact Info

Product

Resources

About